Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound-Guided fluid removal may offer safer relief for overloaded kidneys

NCT ID NCT07705269

Disease control Sponsor: Universidad Autonoma de Nuevo Leon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether a personalized, high-rate fluid removal strategy guided by ultrasound is as safe and effective as the standard rate for patients with advanced kidney disease hospitalized due to severe fluid overload. Participants are randomly assigned to receive either a standard fluid removal rate or a higher rate, with ultrasound used to guide treatment. The goal is to see if the higher rate can relieve symptoms like shortness of breath more quickly without causing dangerous drops in blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-rate ultrafiltration (fluid removal during hemodialysis) guided by ultrasound
What this could lead to
If successful, this approach could offer a safer, faster way to relieve severe fluid overload in hospitalized kidney patients, potentially reducing breathing difficulties and hospital stays.
What could go wrong
This is a small, early-stage trial with only 70 participants, so results may not apply to all patients. The high fluid removal rate could increase the risk of sudden drops in blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults over 18 years old with End-Stage Renal Disease on hemodialysis for at least 3 months. * Admitted to the hospital requiring mechanical fluid removal for acute fluid overload (first in-hospital session). * Clear ultrasound evidence of severe intravascular congestion (such as diffuse B-lines in the lungs or altered VExUS vascular flow patterns). * Hemodynamically stable with a baseline blood pressure of at least 120/80 mmHg. Exclusion Criteria: * Baseline low blood pressure (\<100/60 mmHg) or active shock (cardiogenic, septic, or distributive). * Acute coronary syndrome (heart attack), severe heart valve disease, or severe fluid around the heart. * Known chronic lung disease. * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congestive heart failure(CHF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome congestive heart failure Edema end stage renal failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congestive heart failure(CHF) End stage chronic renal failure Fluid overload Intravascular congestion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario "Dr. José E. González"

    RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.